Pituitary-adrenal suppression and Cushing's syndrome after intermittent dexamethasone therapy.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000328:Adult; D003404:Creatinine / Q000652:urine; D003480:Cushing Syndrome / Q000139:chemically induced*; D003864:Depression, Chemical; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D004487:Edema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012507:Sarcoidosis / Q000188:drug therapy
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D003907:Dexamethasone; D003404:Creatinine; D011241:Prednisone